The genetic basis of myelodysplastic syndromes

Hematology/Oncology Clinics of North America

Volumn 24, Issue 2, 2010, Pages 295-315

  Bejar, Rafael ^a,b   Ebert, Benjamin L ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

Genetic mutations; Karyotypic abnormalities; Myelodysplastic syndromes; Myeloid neoplasms

Indexed keywords

ADDITIONAL SEX COMBS LIKE 1 PROTEIN; CBL PROTEIN; CD135 ANTIGEN; JANUS KINASE 2; K RAS PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEOPHOSMIN; POLYCOMB GROUP PROTEIN; PROTEIN P53; PROTEIN TET2; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CD34 SELECTION; CHROMOSOME 5Q; CHROMOSOME 7Q; CHROMOSOME ADDITION; CHROMOSOME DELETION; CHROMOSOME LOSS; CHROMOSOME TRANSLOCATION; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; CYTOPENIA; EPIGENETICS; GENE AMPLIFICATION; GENE LOCUS; GENETIC ANALYSIS; HEMATOPOIESIS; HUMAN; KARYOTYPE; MYELODYSPLASTIC SYNDROME; NONHUMAN; ONCOGENE K RAS; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRISOMY 8; UNIPARENTAL DISOMY; Y CHROMOSOME;

CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; EPIGENESIS, GENETIC; GENE DOSAGE; GENETIC ASSOCIATION STUDIES; HUMANS; MYELODYSPLASTIC SYNDROMES; POINT MUTATION; TRANSLOCATION, GENETIC; UNIPARENTAL DISOMY;

EID: 77950541015     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.02.001     Document Type: Review

References (126)

1. Haase D., Germing U., Schanz J., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110(13):4385-4395.
2. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89(6):2079-2088.
3. Garcia-Manero G. Demethylating agents in myeloid malignancies. Curr Opin Oncol 2008, 20(6):705-710.
4. Graubert T.A., Payton M.A., Shao J., et al. Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PLoS One 2009, 4(2):e4583.
5. Ebert B.L., Pretz J., Bosco J., et al. Identification of RPS14 as the 5q- syndrome gene by RNA interference screen. Nature 2008, 451(7176):335-339.
6. Draptchinskaia N., Gustavsson P., Andersson B., et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet 1999, 21(2):169-175.
7. McGowan K.A., Li J.Z., Park C.Y., et al. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat Genet 2008, 40(8):963-970.
8. Fumagalli S., Di Cara A., Neb-Gulati A., et al. Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat Cell Biol 2009, 11(4):501-508.
9. Barlow J.L., Drynan L.F., Hewett D.R., et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med 2010, 16:59-66.
10. Liu T.X., Becker M.W., Jelinek J., et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med 2007, 13(1):78-83.
11. Xie H., Hu Z., Chyna B., et al. Human mortalin (HSPA9): a candidate for the myeloid leukemia tumor suppressor gene on 5q31. Leukemia 2000, 14(12):2128-2134.
12. Joslin J.M., Fernald A.A., Tennant T.R., et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 2007, 110(2):719-726.
13. Ebert B.L. Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia 2009, 23(7):1252-1256.
14. Grisendi S., Bernardi R., Rossi M., et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005, 437(7055):147-153.
15. Sportoletti P., Grisendi S., Majid S.M., et al. Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood 2008, 111(7):3859-3862.
16. List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355(14):1456-1465.
17. Wei S., Chen X., Rocha K., et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A 2009, 106(31):12974-12979.
18. Pellagatti A., Jadersten M., Forsblom A.M., et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A 2007, 104(27):11406-11411.
19. Beau M.M., Espinosa R., Davis E.M., et al. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 1996, 88(6):1930-1935.
20. Liang H., Fairman J., Claxton D.F., et al. Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci. Proc Natl Acad Sci U S A 1998, 95(7):3781-3785.
21. Gondek L.P., Tiu R., O'Keefe C.L., et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD and MDS-derived AML. Blood 2008, 111(3):1534-1542.
22. Roulston D., Espinosa R., Stoffel M., et al. Molecular genetics of myeloid leukemia: identification of the commonly deleted segment of chromosome 20. Blood 1993, 82(11):3424-3429.
23. Wang P.W., Eisenbart J.D., Espinosa R., et al. Refinement of the smallest commonly deleted segment of chromosome 20 in malignant myeloid diseases and development of a PAC-based physical and transcription map. Genomics 2000, 67(1):28-39.
24. Liu Y.-C., Ito Y., Hsiao H.-H., et al. Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited. Cancer Genet Cytogenet 2006, 171(1):9-16.
25. Virtaneva K., Wright F.A, Tanner S.M., et al. Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci U S A 2001, 98(3):1124-1129.
26. Sloand E.M., Pfannes L., Chen G., et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood 2007, 109(6):2399-2405.
27. Barrett A.J., Sloand E. Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance. Haematologica 2009, 94(4):449-451.
28. Sloand E.M., Mainwaring L., Fuhrer M., et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005, 106(3):841-851.
29. Wiktor A., Rybicki B.A., Piao Z.S., et al. Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes Cancer 2000, 27(1):11-16.
30. Wong A.K., Fang B., Zhang L., et al. Loss of the Y chromosome: an age-related or clonal phenomenon in acute myelogenous leukemia/myelodysplastic syndrome?. Arch Pathol Lab Med 2008, 132(8):1329-1332.
31. Look A.T. Molecular pathogenesis of MDS. Hematology Am Soc Hematol Educ Program 2005, 2005:156-160.
32. Poppe B., Dastugue N., Vandesompele J., et al. EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements. Genes Chromosomes Cancer 2006, 45(4):349-356.
33. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114(5):937-951.
34. Shapira M.Y., Hirshberg B., Amir G., et al. 6;9 translocation in myelodysplastic syndrome. Cancer Genet Cytogenet 1999, 112(1):57-59.
35. Nucifora G., Begy C.R., Kobayashi H., et al. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. Proc Natl Acad Sci U S A 1994, 91(9):4004-4008.
36. Raza-Egilmez S.Z., Jani-Sait S.N., Grossi M., et al. NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia. Cancer Res 1998, 58(19):4269-4273.
37. Steensma D.P., Neiger J.D., Porcher J.C., et al. Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes. Cancer Res 2009, 69(19):7518-7523.
38. Lahortiga I., Agirre X., Belloni E., et al. Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells. Oncogene 2004, 23(1):311-316.
39. Xinh P.T., Tri N.K., Nagao H., et al. Breakpoints at 1p36.3 in three MDS/AML(M4) patients with t(1;3)(p36;q21) occur in the first intron and in the 5′ region of MEL1. Genes Chromosomes Cancer 2003, 36(3):313-316.
40. Bordereaux D., Fichelson S., Tambourin P., et al. Alternative splicing of the Evi-1 zinc finger gene generates mRNAs which differ by the number of zinc finger motifs. Oncogene 1990, 5(6):925-927.
41. Soderholm J., Kobayashi H., Mathieu C., et al. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator. Leukemia 1997, 11(3):352-358.
42. Morishita K., Parker D.S., Mucenski M.L., et al. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 1988, 54(6):831-840.
43. Du Y., Jenkins N.A., Copeland N.G. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood 2005, 106(12):3932-3939.
44. Russell M., List A., Greenberg P., et al. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood 1994, 84(4):1243-1248.
45. Barjesteh van Waalwijk van Doorn-Khosrovani S., Erpelinck C., van Putten W.L.J., et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003, 101(3):837-845.
46. Buonamici S., Li D., Chi Y., et al. EVI1 induces myelodysplastic syndrome in mice. J Clin Invest 2004, 114(5):713-719.
47. Maresso K., Broeckel U., Rao D.C., et al. Genotyping platforms for mass-throughput genotyping with snps, including human genome-wide scans, in advances in genetics 2008, Adv Genet, 60:107-39.
48. Nishida N., Koike A., Tajima A., et al. Evaluating the performance of Affymetrix SNP Array 6.0 platform with 400 Japanese individuals. BMC Genomics 2008, 9:431.
49. Gondek L.P., Dunbar A.J., Szpurka H., et al. SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD. PLoS One 2007, 2(11):e1225.
50. Heinrichs S., Kulkarni R.V., Bueso-Ramos C.E., et al. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia 2009, 23(9):1605-1613.
51. Mohamedali A., Gaken J., Twine N.A., et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007, 110(9):3365-3373.
52. Tiu R.V., Gondek L.P., O'Keefe C.L., et al. New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. J Clin Oncol 2009, 27(31):5219-5226.
53. Lorsbach R.B., Moore J., Mathew S., et al. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 2003, 17(3):637-641.
54. Delhommeau F., Dupont S., Valle V.D., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360(22):2289-2301.
55. Jankowska A.M., Szpurka H., Tiu R.V., et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009, 113(25):6403-6410.
56. Abdel-Wahab O., Mullally A., Hedvat C., et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114(1):144-147.
57. Mohamedali A.M., Smith A.E., Gaken J., et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol 2009, 27(24):4002-4006.
58. Saint-Martin C., Leroy G., Delhommeau F., et al. Analysis of the Ten-Eleven Translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood 2009, 114(8):1628-1632.
59. Tefferi A., Levine R.L., Lim K.H., et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009, 23(5):900-904.
60. Tefferi A., Lim K.H., Abdel-Wahab O., et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009, 23(7):1343-1345.
61. Mullighan C.G. TET2 mutations in myelodysplasia and myeloid malignancies. Nat Genet 2009, 41(7):766-767.
62. Levine R.L., Carroll M. A common genetic mechanism in malignant bone marrow diseases. N Engl J Med 2009, 360(22):2355-2357.
63. Kosmider O., Gelsi-Boyer V., Cheok M., et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009, 114(15):3285-3291.
64. Langemeijer S.M., Kuiper R.P., Berends M., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009, 41(7):838-842.
65. Kosmider O., Gelsi-Boyer V., Ciudad M., et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009, 94(12):1676-1681.
66. Tahiliani M., Koh K.P., Shen Y., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324(5929):930-935.
67. Cho Y.-S., Kim E-J., Park U-H, et al. Additional Sex Comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor. J Biol Chem 2006, 281(26):17588-17598.
68. Lee S.-W., Cho Y-S, Na J-M., et al. Additional sex comb-like 1 represses RAR-mediated transcription through associating with heterochromatin protein 1 and lysine-specific demethylase 1. J Biol Chem 2010, 285(1):18-29.
69. Gelsi-Boyer V., Trouplin V., Adelaide J., et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009, 145(6):788-800.
70. Carbuccia N., Murati A., Trouplin V., et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009, 23(11):2183-2186.
71. Carbuccia N., Trouplin V., Gelsi-Boyer V., et al. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia 2010, 24(2):469-473.
72. Fisher C.L., Pineault N., Brookes C., et al. Loss-of-function additional sex combs-like1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 2010, 115(1):38-46.
73. Sargin B., Choudhary C., Crosetto N., et al. Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood 2007, 110(3):1004-1012.
74. Saur S.J., Sangkhae V., Geddis A.E., et al. Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. Blood 2010, 115(6):1254-1263.
75. Thien C.B., Langdon W.Y. Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2001, 2(4):294-307.
76. Dunbar A.J., Gondek L.P., O'Keefe C.L., et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 2008, 68(24):10349-10357.
77. Sanada M., Suzuki T., Shih L-Y., et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009, 460(7257):904-908.
78. Caligiuri M.A., Briesewitz R., Yu J., et al. Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood 2007, 110(3):1022-1024.
79. Abbas S., Rotmans G., Lowenberg B., et al. Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias. Haematologica 2008, 93(10):1595-1597.
80. Reindl C., Quentmeier H., Petropoulos K., et al. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin Cancer Res 2009, 15(7):2238-2247.
81. Loh M.L., Sakai D.S., Flotho C., et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 2009, 114(9):1859-1863.
82. Hirai H., Kobayashi Y., Mano H., et al. A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature 1987, 327(6121):430-432.
83. Lyons J., Janssen J.W., Bartram C., et al. Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes. Blood 1988, 71(6):1707-1712.
84. Paquette R.L., Landaw E.M., Pierre R.V., et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993, 82(2):590-599.
85. Constantinidou M., Chalevelakis M., Economopoulos T., et al. Codon 12 ras mutations in patients with myelodysplastic syndrome: incidence and prognostic value. Ann Hematol 1997, 74(1):11-14.
86. Nakagawa T., Saitoh S., Imoto S., et al. Multiple point mutation of N- ras and K- ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia. Oncology 1992, 49(2):114-122.
87. Shih L.Y., Huang C.F., Wang P.N., et al. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 2004, 18(3):466-475.
88. Loh M.L., Martinelli S., Cordeddu V., et al. Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Res 2005, 29(4):459-462.
89. Christiansen D.H., Andersen M.K., Desta F., et al. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2005, 19(12):2232-2240.
90. Christiansen D.H., Andersen M.K., Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001, 19(5):1405-1413.
91. Wattel E., Preudhomme C., Hecquet B., et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994, 84(9):3148-3157.
92. Harada H., Harada Y., Tanaka H., et al. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood 2003, 101(2):673-680.
93. Pedersen-Bjergaard J., Christiansen D.H., Desta F., et al. Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2006, 20(11):1943-1949.
94. Kaneko H., Misawa S., Horiike S., et al. TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood 1995, 85(8):2189-2193.
95. Horiike S., Kita-Sasai Y., Nakao M., et al. Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome. Leuk Lymphoma 2003, 44(6):915-922.
96. Kita-Sasai Y., Horiike S., Misawa S., et al. International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. Br J Haematol 2001, 115(2):309-312.
97. Jadersten M., Saft L., Pellagatti A., et al. Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica 2009, 94(12):1762-1766.
98. Growney J.D., Shigematsu H., Li Z., et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood 2005, 106(2):494-504.
99. Steensma D.P., Gibbons R.J., Mesa R.A., et al. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. Eur J Haematol 2005, 74(1):47-53.
100. Chen C.Y., Lin L.I., Tang J.L., et al. RUNX1 gene mutation in primary myelodysplastic syndrome-the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol 2007, 139(3):405-414.
101. Christiansen D.H., Andersen M.K., Pedersen-Bjergaard J. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood 2004, 104(5):1474-1481.
102. Pedersen-Bjergaard J., Andersen M.K., Andersen M.T., et al. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2008, 22(2):240-248.
103. Harada H., Harada Y., Niimi H., et al. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 2004, 103(6):2316-2324.
104. Harada Y., Harada H. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations. J Cell Physiol 2009, 220(1):16-20.
105. Matheny C.J., Speck M.E., Cushing P.R., et al. Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles. EMBO J 2007, 26(4):1163-1175.
106. Watanabe-Okochi N., Kitaura J., Ono R., et al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 2008, 111(8):4297-4308.
107. Preudhomme C., Renneville A., Bourdon V., et al. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood 2009, 113(22):5583-5587.
108. Owen C.J., Toze C.L., Koochin A., et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood 2008, 112(12):4639-4645.
109. Niimi H., Harada H., Harada Y., et al. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. Leukemia 2006, 20(4):635-644.
110. Levine R.L., Gilliland D.G. Myeloproliferative disorders. Blood 2008, 112(6):2190-2198.
111. Steensma D.P., Dewald G.W., Lasho T.L., et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both " atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005, 106(4):1207-1209.
112. Malcovati L., Della Porta M.G., Pietra D., et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood 2009, 114(17):3538-3545.
113. Boissinot M., Garand R., Hamidou M., et al. The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS). Blood 2006, 108(5):1781-1782.
114. Wardrop D., Steensma D.P. Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category?. Br J Haematol 2009, 144(6):809-817.
115. Hellstrom-Lindberg E., Cazzola M. The role of JAK2 mutations in RARS and other MDS. Hematology 2008, 2008(1):52-59.
116. Steensma D.P., Tefferi A. JAK2 V617F and ringed sideroblasts: not necessarily RARS-T. Blood 2008, 111(3):1748.
117. Ingram W., Lea N.C., Cervera J., et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia 2006, 20(7):1319-1321.
118. Boultwood J., Wainscoat J.S. Gene silencing by DNA methylation in haematological malignancies. Br J Haematol 2007, 138(1):3-11.
119. Mahmud M., Stebbing J. Epigenetic modifications in AML and MDS. Leuk Res 2010, 34(2):139-140.
120. Ye Y., McDevitt M.A., Guo M., et al. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. Cancer Res 2009, 69(21):8482-8490.
121. Benetatos L., Hatzimichael E., Dasoula A., et al. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res 2010, 34(2):148-153.
122. Daskalakis M., Nguyen T.T., Nguyen C., et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 2002, 100(8):2957-2964.
123. Nakamaki T., Bartram C., Seriu T., et al. Molecular analysis of the cyclin-dependent kinase inhibitor genes, p15, p16, p18 and p19 in the myelodysplastic syndromes. Leuk Res 1997, 21(3):235-240.
124. Jiang Y., Dunbar A., Gondek L.P., et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009, 113(6):1315-1325.
125. Kelly L.M., Gilliland D.G. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002, 3:179-198.
126. Mardis E.R., Ding L., Dooling D.J., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 361(11):1058-1066.